SEMA3B and cancer: The 5-year overall survival rate analysis showed that the survival rate of patients with low SEMA3B-AS1 expression in cancer tissues was significantly lower than that of patients with high SEMA3B-AS1 expression in cancer tissues (9/27 (33.33%) vs. 9/14 (64.29%) p < 0.05).